Zitelmi-H Tablet is a combination antihypertensive medication containing Telmisartan 40 mg and Hydrochlorothiazide 12.5 mg. Telmisartan, an angiotensin II receptor blocker (ARB), selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby preventing vasoconstriction and aldosterone secretion, resulting in vasodilation and reduced blood pressure. Hydrochlorothiazide is a thiazide diuretic that promotes sodium and water excretion by inhibiting sodium reabsorption in the distal convoluted tubules of the kidney, contributing to decreased blood volume and peripheral resistance. This synergistic combination effectively manages hypertension, improving blood pressure control in patients inadequately responsive to monotherapy. Zitelmi-H is indicated for the treatment of essential hypertension and may reduce the risk of cardiovascular events associated with high blood pressure. The tablet should be administered once daily, with or without food, as directed by a healthcare professional. Caution is advised in patients with renal or hepatic impairment, electrolyte imbalances, or hypersensitivity to sulfonamides. Regular monitoring of blood pressure, renal function, and electrolytes is recommended during therapy. Adverse effects may include dizziness, hypotension, electrolyte disturbances, and gastrointestinal discomfort. Zitelmi-H should be used under medical supervision to optimize therapeutic outcomes and minimize risks.